United Therapeutics has high revenue growth and low debt. Read why UTHR stock is undervalued with solid financial metrics and ...

United Therapeutics Corporation (NASDAQ ... and again what is normally a seasonally weak fourth quarter for specialty pharmacy ordering. In the fourth quarter, we saw record patient shipments ...

United Therapeutics Corp. operates as a biotechnology company, which engages in the development and commercialization of unique products to address the unmet medical needs of patients with chronic ...

Specialty pharmacy profit pools are still growing ... running tests on a biotechnology product. United Therapeutics Corporation (NASDAQ:UTHR) is a biotechnology company specializing in treatments ...

UNITED THERAPEUTICS ($UTHR) posted quarterly earnings results on Wednesday, February 26th. The company reported earnings of $6.19 per share, missing estimates of $6. ...

A month has gone by since the last earnings report for United Therapeutics (UTHR). Shares have lost about 4.8% in that time frame, underperforming the S&P 500. Will the recent negative trend ...

Envestnet Portfolio Solutions Inc. boosted its holdings in United Therapeutics Co. (NASDAQ:UTHR – Free Report) by 8.1% during the fourth quarter, according to its most recent Form 13F filing with the ...

BofA lowered the firm’s price target on United Therapeutics (UTHR) to $314 from $328 and keeps an Underperform rating on the shares. The firm ...

Commonwealth Equity Services LLC increased its holdings in United Therapeutics Co. (NASDAQ:UTHR – Free Report) by 3.7% during ...

Coming in No. 3 on Fast Company's Queer 50 list, is Martine Rothblatt, the founder and CEO of United Therapeutics. She's also a lawyer, satellite entrepreneur, and futurist. See the innovative ...